Trade Mark Journal No.2021/053 31 December 2021

WO0000001630189 (5,42)

Office of origin: United States of America

Date of International Registration:2 November 2021
Date of designation in the UK: 2 November 2021
Image for mark 1630189 COBALT

International priority date claimed: 19 May 2021 (United States of America) (90722349)
Class 5
Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer.
Class 42
Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; gene editing, namely, pharmaceutical research and development.

Crispr Therapeutics AG

Representative: Tiffany D. Gehrke Marshall, Gerstein & Borun LLP, 233 South Wacker Drive, 6300 Willis Tower, Chicago IL 60606, UNITED STATES OF AMERICA